|
KMID : 0869620130300040320
|
|
Journal of Korean Society of Hospital Pharmacists
2013 Volume.30 No. 4 p.320 ~ p.329
|
|
|
Comparison of Side Effects between L-asparaginase and PEG-L-asparaginase in Pediatric Acute Lymphoblastic Leukemia Patients
|
|
Geum Min-Jung
Park In-Hye
Ko Jong-Hee
Ahn Ji-Hyune
Kim Sung-Eun
Seok Hyun-Joo
|
|
|
Abstract
|
|
|
L-asparaginase (L-asp) is an essential drug for the treatment of acute lymphoblastic leukemia (ALL). However, it requires attention for several side effects. PEG-L-asparaginase (PEG-L-asp), which is formed by the covalent linkage of L-asp to polyethylene glycol (PEG), is also not safe from side effects. In this study, we considered 6 side effects (hypersensitivity, acute pancreatitis, coagulopathy, hyperglycemia, hepatotoxicity and elevation of blood ammonia levels) from 60 pediatric ALL patients who received L-asp and PEG-L-asp in severance hospitals between 2006 and 2010. Among them, 22 patients received only L-asp, and 38 patients were converted from L-asp to PEG-L-asp. Differences were evaluated by the chi-square test and Fisher exact test on the SAS software (version 9.2). Elevation of blood ammonia levels (P=0.0050), hypersensitivity (P=0.1219), bleeding risk (P=0.2839), and hyperglycemia (P=0.6194) were more frequent in the L-asp group. Hepatotoxicity (P=0.1968), thromboembolism (P=0.6432), and acute pancreatitis (P=0.7321) were more frequent in
the PEG-L-asp group. The incidence for each side effect depends not only on the drug itself, but also on the patients’risk, treatment phase and so on. Hypersensitivity by treatment phase (P=0.0109) and bleeding tendency by patients’risk (P=0.0057) show statistical differences. Through this study, we would like to obtain supportive evidence and contribute to the safe consumption of drugs for children with ALL.
|
|
|
KEYWORD
|
|
|
Pediatric ALL, L-asparaginase, PEG-L-asparaginase, Side effects
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|